1. bookVolume 54 (2020): Edition 4 (December 2020)
Radiology and Oncology's Cover Image
Radiology and Oncology
Détails du magazine
License
Format
Magazine
eISSN
1581-3207
Première parution
30 Apr 2007
Périodicité
4 fois par an
Langues
Anglais
Accès libre

The influence of genetic variability in IL1B and MIR146A on the risk of pleural plaques and malignant mesothelioma

Petra Piber,
Petra Piber,
Neza Vavpetic,
Neza Vavpetic,
Katja Goricar,
Katja Goricar,
Vita Dolzan,
Vita Dolzan,
Viljem Kovac et
Viljem Kovac et
Alenka Franko
Alenka Franko
Publié en ligne: 21 Oct 2020
Volume & Edition: Volume 54 (2020) - Edition 4 (December 2020)
Pages: 429 - 436
Reçu: 07 Jul 2020
Accepté: 06 Aug 2020
Radiology and Oncology's Cover Image
Radiology and Oncology
Détails du magazine
License
Format
Magazine
eISSN
1581-3207
Première parution
30 Apr 2007
Périodicité
4 fois par an
Langues
Anglais
Introduction

Asbestos exposure is related to several pleural diseases, such as pleural plaques, diffuse pleural thickenings, pleural effusions and malignant mesothelioma (MM). MM is an aggressive form of cancer found on the mesothelium, generally on the pleura (65%), peritoneum (30%) or other serosal membranes (1%).1, 2

MM is often diagnosed in its later stages, is rarely operable and can respond poorly to conventional chemotherapy.3 Clinical signs and symptoms are uncharacteristic and reminiscent of many other pulmonary diseases. Patients often experience dyspnea, chest pain, weight loss and fatigue. Only a small proportion of MM patients are asymptomatic at the time of diagnosis.2, 4 Average life expectancy is around 7 months with support therapy and 12 months with chemotherapy.5 MM most often occurs in patients older than 65 years.2, 6 Epidemiological studies have shown that the main cause of MM is asbestos exposure, with the incidence of this cancer still increasing due to the long latent period.7 Genetic factors have also been suggested to influence the development of MM; patients often have mutations in tumour suppressor genes, such as BAP1, CDKN2A and NF2.8, 9

Along with MM, asbestos exposure is also related to the development of pleural plaques. Pleural plaques are white and yellow thickenings of pleura, often asymmetrical and bilateral. Histologically, they are acellular, composed of hyalinised collagen, which is covered by one layer of mesothelial cells. Half of the patients with a history of asbestos exposure develop pleural plaques, typically 20 to 30 years after exposure. The risk of pleural plaques rises with the length of asbestos exposure.10 It has been proposed that inflammation caused by asbestos is involved in the pathogenesis of both pleural plaques and MM.3, 11 Asbestos fibres are known to trigger the release of inflammatory mediators, which leads to the downregulation of apoptosis.3

After inhalation, asbestos fibres reach pleural space and are deposited in mesothelial cells.12 This leads to local inflammatory response and proliferation of mesothelial cells. In vitro studies have shown that the fibres induce inflammation and apoptosis and most of the tissue damage is related to elevated interleukin 1 beta (IL-1β).3 Macrophages accumulate near asbestos deposits and release cytokines, such as IL-1β and tumour necrosis factor alpha (TNF-α).8

In response to asbestos, an intrinsic inflammatory mechanism triggers inflammation via inflammasome NLRP3, which is NLR family pyrin domain containing 3, activated by danger-associated molecular patterns (DAMP) or pathogen-associated molecular patterns (PAMP).13, 14 NLRP3 inflammasome is a protein complex of NLRP3, apoptosis-associated speck-like protein (ASC) and caspase-1, found in macrophages, which triggers a type of apoptosis, known as piroptosis.11, 13, 15 The activation of NLRP3 inflammasome increases the production of IL-1β from its precursor, mediated by caspase-1 and pro-inflammatory mediators from macrophages.8,15,16 IL-1β, coded by IL1B gene, is an inflammatory mediator, found during chronic inflammation and a key player in carcinogenesis.17, 18 It promotes neutrophil recruitment and transcription of NF-κB (nuclear factor kappa B), the latter being known to influence tumour growth and response to chemotherapy.18In vitro studies showed that IL-1β plays an important part in increasing proliferation, leading to a malignant transformation.8

IL-1β release can also be regulated by miRNAs, 21-23 nucleotides long non-coding RNAs, which inhibit translation by binding to the 3′-untranslated region (3′-UTR) of mRNA.19 miRNAs are involved in networks of gene regulation and their expression often changes in cancerous tissue, including MM.20, 21, 22, 23, 24, 25 A key miRNA, influencing the expression of IL1B, is miRNA-146. Two human variants are found; miRNA-146a and miRNA-146b, both assumed to play a role in toll-like receptor (TLR) based signalling and cytokine response.21, 22, 26 Previous studies found that miRNA-146a has an anti-inflammatory function, with its silencing leading to an increase in IL-1β and its induction having the opposite effect.22, 26, 27

Genetic factors, such as single nucleotide polymorphisms (SNPs), may influence protein expression.17, 28, 29IL1B rs16944 (c.-511C>T), located in 5’ untranslated region (UTR), influences the binding of transcription factors.30 Higher levels of IL-1β were found in homozygotes with polymorphic allele, leading to a higher risk of developing chronic inflammation-related diseases, such as diabetes mellitus type 2 and breast cancer.31, 32IL1B rs1143623 (-1464G>C) is also located in 5’ UTR and affects the binding of transcription factors.30 Its polymorphic C allele was associated with a lower risk of developing lung and colorectal carcinoma, due to a lower production and release of IL-1β.28, 29 The relationship between IL1B rs1071676, located in 3’UTR, and carcinogenesis has not yet been established, but as it affects miRNA binding site, it could also influence IL1B expression. SNPs have also been found in genes coding for miRNAs, such as MIR146A rs2910164, which has been related to both higher33 and lower risks34 of malignant transformations, according to previous research.35

To the best of our knowledge, the role of IL1B and MIR146A genetic variability in the development of asbestos-related diseases has not been evaluated so far. The aim of the present study was therefore to evaluate the influence of IL1B and MIR146A polymorphisms on the risk of developing pleural plaques and MM.

Subjects and methods
Subjects

The retrospective case-control study included 277 patients with histologically confirmed pleural or peritoneal MM, treated at the Institute of Oncology Ljubljana between 1 January 2001 and 30 September 2018, 394 patients with pleural plaques and 175 healthy control subjects, all of whom were previously exposed to asbestos. The control group and those with pleural plaques were occupationally exposed to asbestos by working in the factory Salonit Anhovo, Slovenia, and were presented at the State Board for the Recognition of Occupational Asbestos Diseases between January 1999 and December 2003. In 2018, the subjects from the control group were found not to have any asbestos-related disease.

The study was approved by the Slovenian Ethics Committee for Research in Medicine and was carried out according to the Declaration of Helsinki.

Clinical diagnosis

Patients with pleural plaques have been diagnosed based on X-ray and high-resolution computed tomography (HRCT), while MM diagnosis was confirmed by a pathologist based on the histopathology of samples gathered thoracoscopically in the case of the pleural and laparoscopically in the case of the peritoneal type of MM.2,36, 37

Asbestos exposure and smoking

A semiquantative method was used to assess the asbestos exposure. The data on cumulative asbestos exposure expressed in fibres/cm3-years were available for all control subjects, all subjects with pleural plaques except for 6, and for 40 subjects with MM. Based on these data, the asbestos exposure in these subjects was categorised into three groups: low (< 11 fibres/cm3-years), medium (11–20 fibres/cm3-years) and high (> 20 fibres/cm3-years) asbestos exposure. For additional 49 subjects with MM who lacked the data on cumulative asbestos exposure a thorough work history was obtained by an interview performed by a single expert experienced in asbestos exposure assessment. Their exposures were compared with the exposures from the group of patients with known cumulative asbestos exposure and were categorized accordingly into three groups with presumed low, medium and high asbestos exposure.2 For the remaining 188 MM patients, exact data on asbestos exposure were not available.

An interview based on a standardized questionnaire was conducted with the control group and patients with pleural plaques to collect data on smoking, while the medical documentation of the Institute of Oncology of Ljubljana was used to obtain this piece of data for patients with MM.2, 38

Single nucleotide polymorphism (SNP) selection

Using LD Tag SNP Selection,30 dbSNP,39 Ensembl40 and LDlink41 we identified IL1B SNPs, which had the minor allele frequency (MAF) greater than 0.05 in the European population, could influence the expression of IL1B and were located less than 5000 base pairs up- or downstream from the gene. Polymorphism rs1071676, located in 3’UTR as well as rs16944 and rs1146323, located in 5’UTR matched our criteria. Based on miRDB,42 miRTarBase43 and Variation Viewer we identified miRNAs, that could influence IL1B expression and SNPs in the genes coding for these miRNAs. Based on the inclusion criteria, we selected rs2910164, a SNP in miRNA-146a.

Molecular genetic analysis

We isolated DNA from venous blood of 44 patients with MM using E.Z.N.A.® SQ II Blood DNA Kit (Omega Bio-tek, Inc., Norcross, Georgia, USA) following the manufacturer’s instructions. DNA samples of all other subjects had been isolated during previous studies.44 Genotyping was performed using competitive allele-specific PCR (KASP), the KASP Master mix (LGC, Middlesex, UK) and custom KASP Genotyping Assay (LGC, Middlesex, UK) according to the manufacturer’s instructions.

Statistics

Median and interquartile range were used to describe continuous variables, while frequencies were used for categorical variables. To compare the distribution of categorical variables, Fisher’s exact test was performed, while non-parametric Kruskal-Wallis test was used for continuous variables. Deviation from the Hardy-Weinberg equilibrium (HWE) was evaluated using chi-square test. Both additive and dominant genetic models were used in statistical analyses. Univariable and multivariable logistic regression was used to analyse the association between genotypes and asbestos-related diseases (pleural plaques and MM). For the analysis of multiplicative interactions between genotypes, logistic regression models using dummy variables were used. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) for Windows, version 21.0 (IBM Corporation, Armonk, NY, USA).

Results

Characteristics of patients with MM and pleural plaques as well as the control group are shown in Table 1. There was a statistically significant difference between the groups in respect to age (p < 0.001) and asbestos exposure (p < 0.001). MM patients were significantly older than the control group or patients with pleural plaques. Among the subjects with known asbestos exposure, 51.7% of patients with MM had medium or high exposure compared to 23.4% of the control group and 28.4 % of patients with pleural plaques. There was no statistically significant difference between groups regarding gender (p = 0.410) and smoking status (p = 0.267) (Table 1).

Characteristics of subjects included in the study

CharacteristicsControl group N = 175Pleural plaques N = 394Malignant mesothelioma N = 277Testp
GenderMale, N (%)119 (68.0)271 (68.8)202 (72.9)1.757

calculated using Fisher exact test

0.410
Female, N (%)56 (32.0)123 (31.3)75 (27.1)
AgeMedian (25%–75%)55.3 (48.6–63.7)54.9 (48.8–62.7)66.0 (59.0–73.0)151.666

calculated using Kruskal-Wallis test

< 0.001
Low, N (%)134 (76.6)278 (71.6) [6]43 (48.3) [188]26.891

calculated using Fisher exact test

< 0.001
Asbestos exposureMedium, N (%)13 (7.4)41 (10.6)24 (27.0)
High, N (%)28 (16.0)69 (17.8)22 (24.7)
SmokingNo, N (%)94 (53.7)194 (49.4) [1]150 (55.6) [7]2.640

calculated using Fisher exact test

0.267
Yes, N (%)81 (46.3)199 (50.6)120 (44.4)

number of missing data is presented in [] brackets

A further analysis of asbestos exposure showed that medium and high levels of asbestos exposure were associated with an increased risk of MM compared both to the control group (odds ratio [OR] = 3.50; 95% confidence interval [CI] = 2.03–6.02; p < 0.001) and patients with pleural plaques (OR = 2.70; 95% CI = 1.69–4.33; p < 0.001).

Among the patients with MM, 19 (6.9 %) had stage I MM, 61 (22.1 %) were in stage II of the disease, 83 (30.1 %) had stage III and 81 (29.3 %) stage IV MM. Thirty-two patients (11.6 %) had the peritoneal subtype of MM, where stage was not determined and in one patient, the MM stage could not be determined. In our cohort, the most prevalent histological subtype of MM was the epithelioid subtype (206; 74.4 %); however some of the patients had either the biphasic (26; 9.4 %) or sarcomatoid subtype (26; 9.4 %) and in the case of a few patients (19; 6.6 %), the histological subtype was not determined.

A comparison of patients with pleural plaques and healthy controls revealed no statistically significant influence on the risk of pleural plaques for any of the selected polymorphisms, neither in univariable analysis nor after adjustments for age, gender and asbestos exposure (Supplementary Table 1).

The analysis of the association between genetic polymorphisms and MM has shown statistically significant influence of polymorphism MIR146A rs2910164 on the risk of developing MM. Carriers of two polymorphic alleles (genotype CC) had a lower risk of developing MM (OR = 0.31; 95% CI = 0.13–0.73; p = 0.008). There was no influence of other genetic polymorphisms on the development of MM (Table 2).

Association between selected polymorphisms and the risk of developing malignant mesothelioma

SNPGenotypeControls N (%)MM N (%)OR (95% CI)pOR (95% CI)adj1padj1OR (95% CI)adj2padj2
IL1B rs1143623GG88 (50.3)152 (54.9)referencereference
GC67 (38.3)97 (35.0)0.84 (0.56–1.26)0.3960.82 (0.52–1.29)0.3880.56 (0.29–1.05)0.072
CC20 (11.4)28 (10.1)0.81 (0.43–1.52)0.5140.69 (0.35–1.38)0.2940.34 (0.11–1.04)0.060
GC+CC87 (49.7)125 (45.1)0.83 (0.57–1.22)0.3410.79 (0.52–1.20)0.2660.50 (0.28–0.92)0.025
IL1B rs16944TT21 (12.0)36 (13.0)1.10 (0.60–2.02)0.7560.94 (0.48–1.82)0.8490.53 (0.20–1.43)0.210
TC75 (42.9)118 (42.6)1.01 (0.67–1.51)0.9600.98 (0.63–1.52)0.9110.67 (0.36–1.24)0.198
CC79 (45.1)123 (44.4)referencereference
TC+TT96 (54.9)154 (55.6)1.03 (0.70–1.51)0.8780.97 (0.64–1.47)0.8730.63 (0.35–1.13)0.122
IL1B rs1071676GG105 (60.0)165 (59.6)referencereference
GC60 (34.3)98 (35.4)1.04 (0.69–1.56)0.8510.97 (0.62–1.51)0.8951.00 (0.53–1.89)0.993
CC10 (5.7)14 (5.1)0.89 (0.38–2.08)0.7890.96 (0.38–2.41)0.9312.03 (0.70–5.90)0.194
GC+CC70 (40.0)112 (40.4)1.02 (0.69–1.50)0.9270.97 (0.64–1.48)0.8851.15 (0.64–2.08)0.632
MIR146A rs2910164GG94 (53.7)158 (57.0)referencereference
GC64 (36.6)110 (39.7)1.02 (0.69–1.53)0.9130.91 (0.59–1.41)0.6720.67 (0.36–1.25)0.209
CC17 (9.7)9 (3.2)0.31 (0.13–0.73)0.0080.34 (0.14–0.85)0.0200.39 (0.11–1.38)0.144
GC+CC81 (46.3)119 (43.0)0.87 (0.60–1.28)0.4880.79 (0.52–1.21)0.2780.62 (0.34–1.11)0.109

adj1 = adjustment for age and gender; adj2 = adjustment for age, gender and asbestos exposure; CI = confidence interval; MM = malignant mesothelioma; OR = odds ratio; SNP = single nucleotide polymorphism

In multivariable analysis, polymorphism MIR146A rs2910164 remained associated with a decreased risk of developing MM after adjustment for age and gender (OR = 0.34; 95% CI = 0.14–0.85; p = 0.020). However, in the subgroup with asbestos exposure data, MIR146A rs2910164 polymorphism no longer showed statistically significant influence on the risk of MM after adjustment for age, gender and asbestos exposure (OR = 0.39; 95% CI = 0.11– 1.38; p = 0.144) (Table 2). Carriers of at least one polymorphic IL1B rs1143623 (genotype GC or CC) showed a significantly decreased risk of MM after adjustment for age, gender and asbestos exposure (OR = 0.50; 95% CI = 0.28–0.92; p = 0.025) (Table 2).

A comparison of patients with MM and pleural plaques showed that polymorphism MIR146A rs2910164 was statistically significantly associated with the risk of the development of MM compared to pleural plaques (Table 3). Patients that had two polymorphic MIR146A rs2910164 alleles (genotype CC) had a significantly decreased risk of MM compared to pleural plaques (OR = 0.32; 95% CI = 0.15–0.68; p = 0.003). Similarly, after adjustment for gender and age, patients who were homozygotes for polymorphic MIR146A rs2910164 still showed a lower risk of developing MM (OR = 0.33; 95% CI = 0.15–0.75; p = 0.008). In the subgroup with available asbestos exposure data, MIR146A rs2910164 was significantly associated with a decreased MM risk only in the dominant model (OR = 0.59; 95% CI = 0.36–0.99; p = 0.046) (Table 3). Additionally, patients that were homozygotes for the IL1B rs1071676 polymorphism (CC genotype) had an increased risk of developing MM when patients with pleural plaques were used as a control group and the analysis was adjusted for age, gender and asbestos exposure (OR = 2.83; 95% CI = 1.04–7.71; p = 0.042) (Table 3).

Association between selected polymorphisms and the risk of developing malignant mesothelioma compared to pleural plaques

SNPGenotypePleural plaques N (%)MM N (%)OR (95 % CI)pOR (95 % CI)adj1padj1OR (95 % CI)adj2padj2
IL1B rs1143623GG205 (52.0)152 (54.9)referencereference
GC157 (39.8)97 (35.0)0.83 (0.60–1.16)0.2770.88 (0.61–1.27)0.4990.67 (0.39–1.15)0.151
CC32 (8.1)28 (10.1)1.18 (0.68–2.04)0.5541.07 (0.58–1.99)0.8270.65 (0.22–1.86)0.418
GC+CC189 (48.0)125 (45.1)0.89 (0.66–1.21)0.4670.92 (0.65–1.29)0.6170.67 (0.40–1.11)0.123
IL1B rs16944TT50 (12.7)36 (13.0)1.02 (0.63–1.67)0.9230.96 (0.56–1.67)0.8970.54 (0.22–1.34)0.184
TC169 (42.9)118 (42.6)0.99 (0.71–1.38)0.9690.98 (0.68–1.42)0.9290.70 (0.41–1.19)0.186
CC175 (44.4)123 (44.4)referencereference
TC+TT219 (55.6)154 (55.6)1.00 (0.73–1.36)0.9980.98 (0.69–1.38)0.9050.66 (0.40–1.10)0.110
IL1B rs1071676GG233 (59.1)165 (59.6)referencereference
GC145 (36.8)98 (35.4)0.95 (0.69–1.32)0.7780.93 (0.65–1.34)0.7080.92 (0.53–1.60)0.774
CC16 (4.1)14 (5.1)1.24 (0.59–2.60)0.5781.29 (0.56–2.97)0.5532.83 (1.04–7.71)0.042
GC+CC161 (40.9)112 (40.4)0.98 (0.72–1.34)0.9110.97 (0.68–1.37)0.8491.09 (0.66–1.82)0.731
MIR146A rs2910164GG196 (49.7)158 (57.0)referencereference
GC163 (41.4)110 (39.7)0.84 (0.61–1.15)0.2760.84 (0.58–1.20)0.3260.65 (0.38–1.11)0.118
CC35 (8.9)9 (3.2)0.32 (0.15–0.68)0.0030.33 (0.15–0.75)0.0080.34 (0.11–1.09)0.069
GC+CC198 (50.3)119 (43.0)0.75 (0.55–1.02)0.0630.74 (0.53–1.05)0.0920.59 (0.36–0.99)0.046

adj1 = adjustment for age and gender; adj2 = adjustment for age, gender and asbestos exposure; CI = confidence interval; MM = malignant mesothelioma; OR = odds ratio; SNP = single nucleotide polymorphism

In further logistic regression modelling, the interactions between polymorphisms showed no significant influence on the risk of pleural plaques (data not shown). The analysis of the influence of the interaction between IL1B rs1143623 and IL1B rs1071676 polymorphisms showed significant influence on the increased MM risk (OR = 2.24, 95% CI = 1.00–5.00, p = 0.050). No other interactions between polymorphisms had a statistically significant influence on the risk of MM (Supplementary Table 2).

Discussion

The association between MM and asbestos exposure has first been described in 1960 and, although very few genetic factors have been studied, multiple factors have since then been considered to influence the pathogenesis of MM.45 In the present study, we evaluated the effect of polymorphisms of IL-1β and miRNA-146a genes on the risk of developing MM and pleural plaques. The key finding of the present study was the association between MIR146A rs2910164 and lower risk of the development of MM.

Consistent with the previous studies, the average age of MM patients was found to be higher than that of the patients with pleural plaques or the control group, probably due to the long latency period between the first asbestos exposure and MM.2, 6, 44 Our study showed no significant association between smoking and MM, which is in agreement with previous findings.2, 44, 46 Subjects with high or medium exposure to asbestos had a higher risk of developing MM, compared to the group with pleural plaques or the control group. Regardless of that, almost half (48.3%) of MM patients were exposed to low levels of asbestos, which is consistent with previous studies claiming there is no threshold level for the development of MM.47, 48

It is not yet clear to what an extent the pleural plaques present a risk factor for MM. The studies performed so far suggested that pleural plaques are more a sign of asbestos exposure, than a carcinogenic factor.49, 50 This hypothesis is in agreement with the findings of this study as the genotype frequency distribution of patients with pleural plaques was found to be more similar to that of the control group, rather than the genotype frequency distribution of patients with MM.

Compared to both the control group and the patients with pleural plaques, homozygotes with polymorphic MIR146A rs2910164 C allele were at a lower risk of developing MM, even after adjustment for age and gender. In the subgroup of patients with known asbestos exposure, carriers of at least one polymorphic MIR146A rs2910164 allele had a lower risk of MM in comparison to patients with pleural plaques.

According to our knowledge, the relation between MIR146A rs2910164 and MM has not yet been studied, but the polymorphism itself has already been associated with several other malignant diseases. Previous studies suggested that the polymorphic allele C had a protective function in the oncogenesis of melanoma51 and non-small cell lung carcinoma33, while the same was found for the G allele in case of papillary thyroid tumour.52 The association of rs2910164 with the pathogenesis of MM could be explained with its influence in miR-NA expression: CC genotype was previously associated with a greater production of miRNA-146a in cancerous tissue.53, 54, 55 Increased expression of miRNA-146a in turn leads to the suppression of inflammatory pathways, reducing the expression of proinflammatory cytokines IL-1β, IL-6 and TNFα,56 while miRNA-146a inhibition has been shown to increase production of those cytokines, resulting in greater inflammatory response to asbestos, promoting carcinogenesis and increasing the risk of MM.17, 18 The role and expression of miRNA-146a in carcinogenesis is still unclear, as some studies found the levels of miRNA-146a to be decreased in cancerous tissue of the lung57 and stomach carcinoma,58 while other studies found increased levels in the cases of melanoma,51 cervical cancer59 and papillary thyroid cancer.52 It is possible that miR-NA-146a has a tissue-specific function, so further studies are required.

Another important finding of this study has been the association between the polymorphic IL1B rs1143623 allele and a lower risk of developing MM. In the subgroup of subjects with known asbestos exposure, subjects with at least one polymorphic C allele had a lower risk of developing MM compared to the control group. IL1B rs1143623 is located at the biding site of the transcription factors and can lower the expression of IL1B.30, 39 Lower levels of IL-1β result in a less intensive inflammatory reaction caused by the asbestos fibres, which could have a protective effect. The former is in agreement with the studies that showed subjects with one polymorphic C allele having a lower risk of developing lung cancer28 and homozygotes for the polymorphic C allele having a lower risk of developing colorectal cancer.29

Finally, this study has shown that the interaction between IL1B rs1143623 and IL1B rs1071676 is associated with a higher risk of developing MM, even though IL1B rs1071676 independently had no effect on the risk of MM, while IL1B rs1143623 was associated with a lower risk of MM within the subgroup of subjects with known asbestos exposure. IL1B rs1143623 was associated with a lower risk of MM only among carriers of two wild type IL1B rs1071676 alleles. As IL1B rs1143623 can influence the binding of transcription factors and rs1071676 can influence the binding of miRNA, the interaction of both polymorphisms could result in a greater expression of IL-1β, however this has not been studied yet.30 Further studies are needed to explain the role of IL1B rs1143623 and its interactions with other polymorphisms and environmental factors in MM.

Lack of asbestos exposure information for all the subjects has been identified as the limitation of our study. Therefore, the subgroup for which asbestos exposure has been taken into consideration, was smaller than the overall sample. This could account for the discrepancy between the results of the analysis adjusted for asbestos exposure and the results of the analysis that did not take asbestos exposure into account. The strength of this study is its large sample size. To the best of our knowledge, this is also the first study researching the effect of IL1B and MIR146A polymorphisms on the risk of developing MM.

In conclusion, our results suggest that IL1B and MIR146A polymorphisms may contribute to the risk of MM development. Further studies, possibly evaluating serum or tissue protein expression, are needed to confirm these associations in independent patient cohorts and elucidate the role of IL-1β and miRNA-146a in the development of asbestos-related diseases.

Association between selected polymorphisms and the risk of developing malignant mesothelioma compared to pleural plaques

SNPGenotypePleural plaques N (%)MM N (%)OR (95 % CI)pOR (95 % CI)adj1padj1OR (95 % CI)adj2padj2
IL1B rs1143623GG205 (52.0)152 (54.9)referencereference
GC157 (39.8)97 (35.0)0.83 (0.60–1.16)0.2770.88 (0.61–1.27)0.4990.67 (0.39–1.15)0.151
CC32 (8.1)28 (10.1)1.18 (0.68–2.04)0.5541.07 (0.58–1.99)0.8270.65 (0.22–1.86)0.418
GC+CC189 (48.0)125 (45.1)0.89 (0.66–1.21)0.4670.92 (0.65–1.29)0.6170.67 (0.40–1.11)0.123
IL1B rs16944TT50 (12.7)36 (13.0)1.02 (0.63–1.67)0.9230.96 (0.56–1.67)0.8970.54 (0.22–1.34)0.184
TC169 (42.9)118 (42.6)0.99 (0.71–1.38)0.9690.98 (0.68–1.42)0.9290.70 (0.41–1.19)0.186
CC175 (44.4)123 (44.4)referencereference
TC+TT219 (55.6)154 (55.6)1.00 (0.73–1.36)0.9980.98 (0.69–1.38)0.9050.66 (0.40–1.10)0.110
IL1B rs1071676GG233 (59.1)165 (59.6)referencereference
GC145 (36.8)98 (35.4)0.95 (0.69–1.32)0.7780.93 (0.65–1.34)0.7080.92 (0.53–1.60)0.774
CC16 (4.1)14 (5.1)1.24 (0.59–2.60)0.5781.29 (0.56–2.97)0.5532.83 (1.04–7.71)0.042
GC+CC161 (40.9)112 (40.4)0.98 (0.72–1.34)0.9110.97 (0.68–1.37)0.8491.09 (0.66–1.82)0.731
MIR146A rs2910164GG196 (49.7)158 (57.0)referencereference
GC163 (41.4)110 (39.7)0.84 (0.61–1.15)0.2760.84 (0.58–1.20)0.3260.65 (0.38–1.11)0.118
CC35 (8.9)9 (3.2)0.32 (0.15–0.68)0.0030.33 (0.15–0.75)0.0080.34 (0.11–1.09)0.069
GC+CC198 (50.3)119 (43.0)0.75 (0.55–1.02)0.0630.74 (0.53–1.05)0.0920.59 (0.36–0.99)0.046

Characteristics of subjects included in the study

CharacteristicsControl group N = 175Pleural plaques N = 394Malignant mesothelioma N = 277Testp
GenderMale, N (%)119 (68.0)271 (68.8)202 (72.9)1.757

calculated using Fisher exact test

0.410
Female, N (%)56 (32.0)123 (31.3)75 (27.1)
AgeMedian (25%–75%)55.3 (48.6–63.7)54.9 (48.8–62.7)66.0 (59.0–73.0)151.666

calculated using Kruskal-Wallis test

< 0.001
Low, N (%)134 (76.6)278 (71.6) [6]43 (48.3) [188]26.891

calculated using Fisher exact test

< 0.001
Asbestos exposureMedium, N (%)13 (7.4)41 (10.6)24 (27.0)
High, N (%)28 (16.0)69 (17.8)22 (24.7)
SmokingNo, N (%)94 (53.7)194 (49.4) [1]150 (55.6) [7]2.640

calculated using Fisher exact test

0.267
Yes, N (%)81 (46.3)199 (50.6)120 (44.4)

Association between selected polymorphisms and the risk of developing malignant mesothelioma

SNPGenotypeControls N (%)MM N (%)OR (95% CI)pOR (95% CI)adj1padj1OR (95% CI)adj2padj2
IL1B rs1143623GG88 (50.3)152 (54.9)referencereference
GC67 (38.3)97 (35.0)0.84 (0.56–1.26)0.3960.82 (0.52–1.29)0.3880.56 (0.29–1.05)0.072
CC20 (11.4)28 (10.1)0.81 (0.43–1.52)0.5140.69 (0.35–1.38)0.2940.34 (0.11–1.04)0.060
GC+CC87 (49.7)125 (45.1)0.83 (0.57–1.22)0.3410.79 (0.52–1.20)0.2660.50 (0.28–0.92)0.025
IL1B rs16944TT21 (12.0)36 (13.0)1.10 (0.60–2.02)0.7560.94 (0.48–1.82)0.8490.53 (0.20–1.43)0.210
TC75 (42.9)118 (42.6)1.01 (0.67–1.51)0.9600.98 (0.63–1.52)0.9110.67 (0.36–1.24)0.198
CC79 (45.1)123 (44.4)referencereference
TC+TT96 (54.9)154 (55.6)1.03 (0.70–1.51)0.8780.97 (0.64–1.47)0.8730.63 (0.35–1.13)0.122
IL1B rs1071676GG105 (60.0)165 (59.6)referencereference
GC60 (34.3)98 (35.4)1.04 (0.69–1.56)0.8510.97 (0.62–1.51)0.8951.00 (0.53–1.89)0.993
CC10 (5.7)14 (5.1)0.89 (0.38–2.08)0.7890.96 (0.38–2.41)0.9312.03 (0.70–5.90)0.194
GC+CC70 (40.0)112 (40.4)1.02 (0.69–1.50)0.9270.97 (0.64–1.48)0.8851.15 (0.64–2.08)0.632
MIR146A rs2910164GG94 (53.7)158 (57.0)referencereference
GC64 (36.6)110 (39.7)1.02 (0.69–1.53)0.9130.91 (0.59–1.41)0.6720.67 (0.36–1.25)0.209
CC17 (9.7)9 (3.2)0.31 (0.13–0.73)0.0080.34 (0.14–0.85)0.0200.39 (0.11–1.38)0.144
GC+CC81 (46.3)119 (43.0)0.87 (0.60–1.28)0.4880.79 (0.52–1.21)0.2780.62 (0.34–1.11)0.109

Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A. Fibulin-3 as a bio-marker of response to treatment in malignant mesothelioma. Radiol Oncol 2015; 49: 279-85. doi: 10.1515/raon-2015-0019KovacVDodic-FikfakMArnericNDolzanVFrankoAFibulin-3 as a bio-marker of response to treatment in malignant mesotheliomaRadiol Oncol2015492798510.1515/raon-2015-0019457722526401134Ouvrir le DOISearch in Google Scholar

Franko A, Kotnik N, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. The influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2018; 52: 105-11. doi: 10.2478/raon-2018-0004FrankoAKotnikNGoricarKKovacVDodic-FikfakMDolzanVThe influence of genetic variability on the risk of developing malignant mesotheliomaRadiol Oncol2018521051110.2478/raon-2018-0004583908829520212Ouvrir le DOISearch in Google Scholar

Acencio MM, Soares B, Marchi E, Silva CS, Teixeira LR, Broaddus VC. Inflammatory cytokines contribute to asbestos-induced injury of mesothelial cells. Lung 2015; 193: 831-7. doi: 10.1007/s00408-015-9744-4AcencioMMSoaresBMarchiESilvaCSTeixeiraLRBroaddusVCInflammatory cytokines contribute to asbestos-induced injury of mesothelial cellsLung2015193831710.1007/s00408-015-9744-426059286Ouvrir le DOISearch in Google Scholar

Bianco A, Valente T, De Rimini ML, Sica G, Fiorelli A. Clinical diagnosis of malignant pleural mesothelioma. J Thorac Dis 2018; 10: S253-61. doi: 10.21037/jtd.2017.10.09BiancoAValenteTDe RiminiMLSicaGFiorelliAClinical diagnosis of malignant pleural mesotheliomaJ Thorac Dis201810S2536110.21037/jtd.2017.10.09583056129507793Ouvrir le DOISearch in Google Scholar

Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-44. doi: 10.2478/v10019-012-0032-0KovacVZwitterMZagarTImproved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patientsRadiol Oncol2012461364410.2478/v10019-012-0032-0347293823077450Ouvrir le DOISearch in Google Scholar

Remon J, Lianes P, Martinez S, Velasco M, Querol R, Zanui M. Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev 2013; 39: 584-91. doi: 10.1016/j.ctrv.2012.12.005RemonJLianesPMartinezSVelascoMQuerolRZanuiMMalignant mesothelioma: new insights into a rare diseaseCancer Treat Rev2013395849110.1016/j.ctrv.2012.12.00523276688Ouvrir le DOISearch in Google Scholar

Plato N, Martinsen JI, Sparen P, Hillerdal G, Weiderpass E. Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos ban. Epidemiol Health 2016; 38: e2016039. doi: 10.4178/epih.e2016039PlatoNMartinsenJISparenPHillerdalGWeiderpassEOccupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos banEpidemiol Health201638e201603910.4178/epih.e2016039511443827866405Ouvrir le DOISearch in Google Scholar

Kadariya Y, Menges CW, Talarchek J, Cai KQ, Klein-Szanto AJ, Pietrofesa RA, et al. Inflammation-related IL1beta/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma. Cancer Prev Res (Phila) 2016; 9: 406-14. doi: 10.1158/1940-6207.CAPR-15-0347KadariyaYMengesCWTalarchekJCaiKQKlein-SzantoAJPietrofesaRAet alInflammation-related IL1beta/IL1R signaling promotes the development of asbestos-induced malignant mesotheliomaCancer Prev Res (Phila)201694061410.1158/1940-6207.CAPR-15-0347485475326935421Ouvrir le DOISearch in Google Scholar

Melaiu O, Gemignani F, Landi S. The genetic susceptibility in the development of malignant pleural mesothelioma. J Thoracic Dis 2018; 10: S246-52. doi: 10.21037/jtd.2017.10.41MelaiuOGemignaniFLandiSThe genetic susceptibility in the development of malignant pleural mesotheliomaJ Thoracic Dis201810S2465210.21037/jtd.2017.10.41583056429507792Ouvrir le DOISearch in Google Scholar

Chapman SJ, Cookson WO, Musk AW, Lee YC. Benign asbestos pleural diseases. Curr Opin Pulm Med 2003; 9: 266-71. doi: 10.1097/00063198200307000-00004ChapmanSJCooksonWOMuskAWLeeYCBenign asbestos pleural diseasesCurr Opin Pulm Med200392667110.1097/00063198200307000-00004Ouvrir le DOISearch in Google Scholar

Franko A, Goricar K, Kovac V, Dodic Fikfak M, Dolzan V. NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases. J Med Biochem 2019; 38: 1-10. doi: 10.2478/jomb-2019-0025FrankoAGoricarKKovacVDodic FikfakMDolzanVNLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseasesJ Med Biochem20193811010.2478/jomb-2019-0025728224232549782Ouvrir le DOISearch in Google Scholar

Chew SH, Toyokuni S. Malignant mesothelioma as an oxidative stress-induced cancer: an update. Free Radic Biol Med 2015; 86: 166-78. doi: 10.1016/j.freeradbiomed.2015.05.002ChewSHToyokuniSMalignant mesothelioma as an oxidative stress-induced cancer: an updateFree Radic Biol Med2015861667810.1016/j.freeradbiomed.2015.05.00225975982Ouvrir le DOISearch in Google Scholar

Hoffman HM, Wanderer AA. Inflammasome and IL-1beta-mediated disorders. Curr Allergy Asthma Rep 2010; 10: 229-35. doi: 10.1007/s11882-010-0109-zHoffmanHMWandererAAInflammasome and IL-1beta-mediated disordersCurr Allergy Asthma Rep2010102293510.1007/s11882-010-0109-z289208320425006Ouvrir le DOISearch in Google Scholar

Kim YK, Shin JS, Nahm MH. NOD-Like receptors in infection, immunity, and diseases. Yonsei Med J 2016; 57: 5-14. doi: 10.3349/ymj.2016.57.1.5KimYKShinJSNahmMHNOD-Like receptors in infection, immunity, and diseasesYonsei Med J20165751410.3349/ymj.2016.57.1.5469697126632377Ouvrir le DOISearch in Google Scholar

Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol Res 2017; 5: 94-9. doi: 10.1158/2326-6066.CIR-16-0269KarkiRManSMKannegantiTDInflammasomes and cancerCancer Immunol Res2017594910.1158/2326-6066.CIR-16-0269559308128093447Ouvrir le DOISearch in Google Scholar

Jenko B, Praprotnik S, Tomsic M, Dolzan V. NLRP3 and CARD8 polymorphisms influence higher disease activity in rheumatoid arthritis. J Med Biochem 2016; 35: 319-23. doi: 10.1515/jomb-2016-0008JenkoBPraprotnikSTomsicMDolzanVNLRP3 and CARD8 polymorphisms influence higher disease activity in rheumatoid arthritisJ Med Biochem2016353192310.1515/jomb-2016-0008534681028356883Ouvrir le DOISearch in Google Scholar

Bhat IA, Naykoo NA, Qasim I, Ganie FA, Yousuf Q, Bhat BA, et al. Association of interleukin 1 beta (IL-1beta) polymorphism with mRNA expression and risk of non small cell lung cancer. Meta Gene 2014; 2: 123-33. doi: 10.1016/j. mgene.2013.12.002BhatIANaykooNAQasimIGanieFAYousufQBhatBAet alAssociation of interleukin 1 beta (IL-1beta) polymorphism with mRNA expression and risk of non small cell lung cancerMeta Gene201421233310.1016/j.mgene.2013.12.002428780325606396Ouvrir le DOISearch in Google Scholar

Hai Ping P, Feng Bo T, Li L, Nan Hui Y, Hong Z. IL-1beta/NF-kb signaling promotes colorectal cancer cell growth through miR-181a/PTEN axis. Arch Biochem Biophys 2016; 604: 20-6. doi: 10.1016/j.abb.2016.06.001Hai PingPFeng BoTLiLNan HuiYHongZIL-1beta/NF-kb signaling promotes colorectal cancer cell growth through miR-181a/PTEN axisArch Biochem Biophys201660420610.1016/j.abb.2016.06.00127264420Ouvrir le DOISearch in Google Scholar

Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA 2005; 11: 1753-61. doi: 10.1261/rna.2248605PillaiRSMicroRNA function: multiple mechanisms for a tiny RNA?RNA20051117536110.1261/rna.2248605137086316314451Ouvrir le DOISearch in Google Scholar

Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans 2008; 36: 1211-5. doi: 10.1042/BST0361211WilliamsAEPerryMMMoschosSALarner-SvenssonHMLindsayMARole of miRNA-146a in the regulation of the innate immune response and cancerBiochem Soc Trans2008361211510.1042/BST036121119021527Ouvrir le DOISearch in Google Scholar

Wang C, Zhang W, Zhang L, Chen X, Liu F, Zhang J, et al. miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2. Br J Cancer 2018; 118: e12. doi: 10.1038/bjc.2017.471WangCZhangWZhangLChenXLiuFZhangJet almiR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2Br J Cancer2018118e1210.1038/bjc.2017.471587743329462128Ouvrir le DOISearch in Google Scholar

Xie YF, Shu R, Jiang SY, Liu DL, Ni J, Zhang XL. MicroRNA-146 inhibits pro-inflammatory cytokine secretion through IL-1 receptor-associated kinase 1 in human gingival fibroblasts. J Inflamm (Lond) 2013; 10: 20. doi: 10.1186/1476-9255-10-20XieYFShuRJiangSYLiuDLNiJZhangXLMicroRNA-146 inhibits pro-inflammatory cytokine secretion through IL-1 receptor-associated kinase 1 in human gingival fibroblastsJ Inflamm (Lond)2013102010.1186/1476-9255-10-20366016323680172Ouvrir le DOISearch in Google Scholar

Xie W, Li Z, Li M, Xu N, Zhang Y. miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo. Biochem Biophys Res Commun 2013; 430: 647-52. doi: 10.1016/j.bbrc.2012.11.097XieWLiZLiMXuNZhangYmiR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivoBiochem Biophys Res Commun20134306475210.1016/j.bbrc.2012.11.09723220232Ouvrir le DOISearch in Google Scholar

Lo Russo G, Tessari A, Capece M, Galli G, de Braud F, Garassino MC, et al. MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a literature review. Front Oncol 2018; 8: 650. doi: 10.3389/ fonc.2018.00650LoRusso GTessariACapeceMGalliGde BraudFGarassinoMCet alMicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a literature reviewFront Oncol2018865010.3389/fonc.2018.00650630814130622932Ouvrir le DOISearch in Google Scholar

Ghaffarzadeh M, Ghaedi H, Alipoor B, Omrani MD, Kazerouni F, Shanaki M, et al. Association of MiR-149 (RS2292832) variant with the risk of coronary artery disease. J Med Biochem 2017; 36: 251-8. doi: 10.1515/ jomb-2017-0005GhaffarzadehMGhaediHAlipoorBOmraniMDKazerouniFShanakiMet alAssociation of MiR-149 (RS2292832) variant with the risk of coronary artery diseaseJ Med Biochem201736251810.1515/jomb-2017-0005628721930568542Ouvrir le DOISearch in Google Scholar

Comer BS, Camoretti-Mercado B, Kogut PC, Halayko AJ, Solway J, Gerthoffer WT. MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2014; 307: L727-34. doi: 10.1152/ajplung.00174.2014ComerBSCamoretti-MercadoBKogutPCHalaykoAJSolwayJGerthofferWTMicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscleAm J Physiol Lung Cell Mol Physiol2014307L7273410.1152/ajplung.00174.2014421700325217662Ouvrir le DOISearch in Google Scholar

Ichii O, Otsuka S, Sasaki N, Namiki Y, Hashimoto Y, Kon Y. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. Kidney Int 2012; 81: 280-92. doi: 10.1038/ki.2011.345IchiiOOtsukaSSasakiNNamikiYHashimotoYKonYAltered expression of microRNA miR-146a correlates with the development of chronic renal inflammationKidney Int2012812809210.1038/ki.2011.34521975861Ouvrir le DOISearch in Google Scholar

Eaton KD, Romine PE, Goodman GE, Thornquist MD, Barnett MJ, Petersdorf EW. Inflammatory gene polymorphisms in lung cancer susceptibility. J Thorac Oncol 2018; 13: 649-59. doi: 10.1016/j.jtho.2018.01.022EatonKDRominePEGoodmanGEThornquistMDBarnettMJPetersdorfEWInflammatory gene polymorphisms in lung cancer susceptibilityJ Thorac Oncol2018136495910.1016/j.jtho.2018.01.022597624229408308Ouvrir le DOISearch in Google Scholar

Qian H, Zhang D, Bao C. Two variants of Interleukin-1B gene are associated with the decreased risk, clinical features, and better overall survival of colorectal cancer: a two-center case-control study. Aging (Albany NY) 2018; 10: 4084-92. doi: 10.18632/aging.101695QianHZhangDBaoCTwo variants of Interleukin-1B gene are associated with the decreased risk, clinical features, and better overall survival of colorectal cancer: a two-center case-control studyAging (Albany NY)20181040849210.18632/aging.101695632665330563955Ouvrir le DOISearch in Google Scholar

Willems P, Claes K, Baeyens A, Vandersickel V, Werbrouck J, De Ruyck K, et al. Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes Cancer 2008; 47: 137-48. doi: 10.1002/gcc.20515WillemsPClaesKBaeyensAVandersickelVWerbrouckJDe RuyckKet alPolymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivityGenes Chromosomes Cancer2008471374810.1002/gcc.2051518000863Ouvrir le DOISearch in Google Scholar

Tayel SI, Fouda EAM, Elshayeb EI, Eldakamawy ARA, El-Kousy SM. Biochemical and molecular study on interleukin-1beta gene expression and relation of single nucleotide polymorphism in promoter region with Type 2 diabetes mellitus. J Cell Biochem 2018; 119: 5343-9. doi: 10.1002/jcb.26667TayelSIFoudaEAMElshayebEIEldakamawyARAEl-KousySMBiochemical and molecular study on interleukin-1beta gene expression and relation of single nucleotide polymorphism in promoter region with Type 2 diabetes mellitusJ Cell Biochem20181195343910.1002/jcb.2666729323730Ouvrir le DOISearch in Google Scholar

Wang J, Shi Y, Wang G, Dong S, Yang D, Zuo X. The association between interleukin-1 polymorphisms and their protein expression in Chinese Han patients with breast cancer. Mol Genet Genomic Med 2019; 7: e804. doi: 10.1002/mgg3.804WangJShiYWangGDongSYangDZuoXThe association between interleukin-1 polymorphisms and their protein expression in Chinese Han patients with breast cancerMol Genet Genomic Med20197e80410.1002/mgg3.804668761631297985Ouvrir le DOISearch in Google Scholar

Jia Y, Zang A, Shang Y, Yang H, Song Z, Wang Z, et al. MicroRNA-146a rs2910164 polymorphism is associated with susceptibility to non-small cell lung cancer in the Chinese population. Med Oncol 2014; 31: 194. doi: 10.1007/s12032-014-0194-2JiaYZangAShangYYangHSongZWangZet alMicroRNA-146a rs2910164 polymorphism is associated with susceptibility to non-small cell lung cancer in the Chinese populationMed Oncol20143119410.1007/s12032-014-0194-225154761Ouvrir le DOISearch in Google Scholar

Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res 2016; 76: 3666-70. doi: 10.1158/0008-5472.CAN-16-0359SvoronosAAEngelmanDMSlackFJOncomiR or tumor suppressor? The duplicity of microRNAs in cancerCancer Res20167636667010.1158/0008-5472.CAN-16-0359493069027325641Ouvrir le DOISearch in Google Scholar

Wei Y, Li L, Gao J. The association between two common polymorphisms (miR-146a rs2910164 and miR-196a2 rs11614913) and susceptibility to gastric cancer: a meta-analysis. Cancer Biomark 2015; 15: 235-48. doi: 10.3233/CBM-150470WeiYLiLGaoJThe association between two common polymorphisms (miR-146a rs2910164 and miR-196a2 rs11614913) and susceptibility to gastric cancer: a meta-analysisCancer Biomark2015152354810.3233/CBM-15047026406571Ouvrir le DOISearch in Google Scholar

Wolff H, Vehmas T, Oksa P, Rantanen J, Vainio H. Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scand J Work Environ Health 2015; 41: 5-15. doi: 10.5271/sjweh.3462WolffHVehmasTOksaPRantanenJVainioHAsbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendationsScand J Work Environ Health20154151510.5271/sjweh.346225299403Ouvrir le DOISearch in Google Scholar

American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170: 691-715. doi: 10.1164/rccm.200310-1436stAmerican Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestosAm J Respir Crit Care Med200417069171510.1164/rccm.200310-1436st15355871Ouvrir le DOISearch in Google Scholar

Dodic Fikfak M, Kriebel D, Quinn MM, Eisen EA, Wegman DH. A case control study of lung cancer and exposure to chrysotile and amphibole at a Slovenian asbestos-cement plant. Ann Occup Hyg 2007; 51: 261-8. doi: 10.1093/annhyg/mem003Dodic FikfakMKriebelDQuinnMMEisenEAWegmanDHA case control study of lung cancer and exposure to chrysotile and amphibole at a Slovenian asbestos-cement plantAnn Occup Hyg200751261810.1093/annhyg/mem00317351264Ouvrir le DOISearch in Google Scholar

Dolzan V. Genetic polymorphisms and drug metabolism. Zdrav Vestn 2007; 76 (Supll II): 5-12.DolzanVGenetic polymorphisms and drug metabolismZdrav Vestn200776Supll II512Search in Google Scholar

Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, et al. Ensembl 2018. Nucleic Acids Res 2018; 46: D754-61. doi: 10.1093/nar/ gkx1098ZerbinoDRAchuthanPAkanniWAmodeMRBarrellDBhaiJet alEnsembl 2018Nucleic Acids Res201846D7546110.1093/nar/gkx1098575320629155950Ouvrir le DOISearch in Google Scholar

Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 2015; 31: 3555-7. doi: 10.1093/ bioinformatics/btv402MachielaMJChanockSJLDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variantsBioinformatics2015313555710.1093/bioinformatics/btv402462674726139635Ouvrir le DOISearch in Google Scholar

Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 2015; 43: D146-52. doi: 10.1093/nar/gku1104WongNWangXmiRDB: an online resource for microRNA target prediction and functional annotationsNucleic Acids Res201543D1465210.1093/nar/gku1104438392225378301Ouvrir le DOISearch in Google Scholar

Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 2018; 46: D296-302. doi: 10.1093/nar/gkx1067ChouCHShresthaSYangCDChangNWLinYLLiaoKWet almiRTarBase update 2018: a resource for experimentally validated microRNA-target interactionsNucleic Acids Res201846D29630210.1093/nar/gkx1067575322229126174Ouvrir le DOISearch in Google Scholar

Levpuscek K, Goricar K, Kovac V, Dolzan V, Franko A. The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma. Radiol Oncol 2019; 53: 206-12. doi: 10.2478/raon-2019-0016LevpuscekKGoricarKKovacVDolzanVFrankoAThe influence of genetic variability of DNA repair mechanisms on the risk of malignant mesotheliomaRadiol Oncol2019532061210.2478/raon-2019-0016657249230893058Ouvrir le DOISearch in Google Scholar

Riva MA, Carnevale F, Sironi VA, De Vito G, Cesana G. Mesothelioma and asbestos, fifty years of evidence: Chris Wagner and the contribution of the Italian occupational medicine community. Med Lav 2010; 101: 409-15. PMID: 21141345RivaMACarnevaleFSironiVADe VitoGCesanaGMesothelioma and asbestos, fifty years of evidence: Chris Wagner and the contribution of the Italian occupational medicine communityMed Lav201010140915PMID: 21141345Search in Google Scholar

Muscat JE, Wynder EL. Cigarette smoking, asbestos exposure, and malignant mesothelioma. Cancer Res 1991; 51: 2263-7. PMID: 2015590MuscatJEWynderELCigarette smoking, asbestos exposure, and malignant mesotheliomaCancer Res19915122637PMID 2015590Search in Google Scholar

Case BW, Abraham JL, Meeker G, Pooley FD, Pinkerton KE. Applying definitions of “asbestos” to environmental and “low-dose” exposure levels and health effects, particularly malignant mesothelioma. J Toxicol Environ Health B Crit Rev 2011; 14: 3-39. doi: 10.1080/10937404.2011.556045CaseBWAbrahamJLMeekerGPooleyFDPinkertonKEApplying definitions of “asbestos” to environmental and “low-dose” exposure levels and health effects, particularly malignant mesotheliomaJ Toxicol Environ Health B Crit Rev20111433910.1080/10937404.2011.556045311848721534084Ouvrir le DOISearch in Google Scholar

Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012; 227: 44-58. doi: 10.1002/jcp.22724CarboneMLyBHDodsonRFPaganoIMorrisPTDoganUAet alMalignant mesothelioma: facts, myths, and hypothesesJ Cell Physiol2012227445810.1002/jcp.22724314320621412769Ouvrir le DOISearch in Google Scholar

Hillerdal G, Henderson DW. Asbestos, asbestosis, pleural plaques and lung cancer. Scand J Work Environ Health 1997; 23: 93-103. doi: 10.5271/ sjweh.186HillerdalGHendersonDWAsbestos, asbestosis, pleural plaques and lung cancerScand J Work Environ Health1997239310310.5271/sjweh.1869167232Ouvrir le DOISearch in Google Scholar

Maxim LD, Niebo R, Utell MJ. Are pleural plaques an appropriate endpoint for risk analyses? Inhal Toxicol 2015; 27: 321-34. doi: 10.3109/08958378.2015.1051640MaximLDNieboRUtellMJAre pleural plaques an appropriate endpoint for risk analyses?Inhal Toxicol2015273213410.3109/08958378.2015.105164026075933Ouvrir le DOISearch in Google Scholar

Forloni M, Dogra SK, Dong Y, Conte D Jr, Ou J, Zhu LJ, et al. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. Elife 2014; 3: e01460. doi: 10.7554/eLife.01460ForloniMDograSKDongYConteD JrOuJZhuLJet almiR-146a promotes the initiation and progression of melanoma by activating Notch signalingElife20143e0146010.7554/eLife.01460392763324550252Ouvrir le DOISearch in Google Scholar

Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci US A 2008; 105: 7269-74. doi: 10.1073/pnas.0802682105JazdzewskiKMurrayELFranssilaKJarzabBSchoenbergDRde la ChapelleACommon SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinomaProc Natl Acad Sci US A200810572697410.1073/pnas.0802682105243823918474871Ouvrir le DOISearch in Google Scholar

Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008; 29: 1963-6. doi: 10.1093/carcin/bgn172ShenJAmbrosoneCBDiCioccioRAOdunsiKLeleSBZhaoHA functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosisCarcinogenesis2008291963610.1093/carcin/bgn17218660546Ouvrir le DOISearch in Google Scholar

Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 2011; 17: 4277-84. doi: 10.1158/1078-0432.CCR-10-2866KogoRMimoriKTanakaFKomuneSMoriMClinical significance of miR-146a in gastric cancer casesClin Cancer Res20111742778410.1158/1078-0432.CCR-10-286621632853Ouvrir le DOISearch in Google Scholar

Zhang W, Yi X, Guo S, Shi Q, Wei C, Li X, et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study. J Cell Mol Med 2014; 18: 2225-34. doi: 10.1111/jcmm.12359ZhangWYiXGuoSShiQWeiCLiXet alA single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional studyJ Cell Mol Med20141822253410.1111/jcmm.12359422455625209759Ouvrir le DOISearch in Google Scholar

Wang JH, Shih KS, Wu YW, Wang AW, Yang CR. Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1beta signaling in osteoarthritis fibroblast-like synoviocytes. Osteoarthritis Cartilage 2013; 21: 1987-96. doi: 10.1016/j.joca.2013.09.008WangJHShihKSWuYWWangAWYangCRHistone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1beta signaling in osteoarthritis fibroblast-like synoviocytesOsteoarthritis Cartilage20132119879610.1016/j.joca.2013.09.00824107356Ouvrir le DOISearch in Google Scholar

Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, et al. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One 2013; 8: e60317. doi: 10.1371/journal. pone.0060317ChenGUmeloIALvSTeugelsEFostierKKronenbergerPet almiR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cellsPLoS One20138e6031710.1371/journal.pone.0060317360858423555954Ouvrir le DOISearch in Google Scholar

Yao Q, Cao Z, Tu C, Zhao Y, Liu H, Zhang S. MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2. Cancer Lett 2013; 335: 219-24. doi: 10.1016/j.canlet.2013.02.031YaoQCaoZTuCZhaoYLiuHZhangSMicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2Cancer Lett20133352192410.1016/j.canlet.2013.02.03123435376Ouvrir le DOISearch in Google Scholar

Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008; 3: e2557. doi: 10.1371/journal. pone.0002557WangXTangSLeSYLuRRaderJSMeyersCet alAberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growthPLoS One20083e255710.1371/journal.pone.0002557243847518596939Ouvrir le DOISearch in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo